Miracor Medical Systems GmbH:製品パイプライン分析

◆英語タイトル:Miracor Medical Systems GmbH - Product Pipeline Analysis, 2017 Update
◆商品コード:DATA8010080
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月27日
◆ページ数:31
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オーストリア
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD1,500 ⇒換算¥222,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD2,250 ⇒換算¥333,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Miracor Medical Systems GmbH (Miracor Medical) is a medical device company that develops and commercializes pressure-controlled intermittent coronary sinus occlusions. The company offers products for continuous monitoring of coronary sinus pressure dynamics. It offers impulse console and impulse catheter, which are based on proprietary platform PICSO technology. Miracor Medical’s technology is used for treatment of acute ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction. The company also conducts post market clinical trials on PICSO impulse system in heart attack patients undergoing coronary revascularization with percutaneous coronary intervention. Miracor Medical is headquartered in Vienna, Austria.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Miracor Medical Systems GmbH
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Miracor Medical Systems GmbH Company Overview 4
Miracor Medical Systems GmbH Company Snapshot 4
Miracor Medical Systems GmbH Pipeline Products and Ongoing Clinical Trials Overview 4
Miracor Medical Systems GmbH – Pipeline Analysis Overview 7
Miracor Medical Systems GmbH – Key Facts 7
Miracor Medical Systems GmbH – Major Products and Services 8
Miracor Medical Systems GmbH Pipeline Products by Development Stage 9
Miracor Medical Systems GmbH Ongoing Clinical Trials by Trial Status 11
Miracor Medical Systems GmbH Pipeline Products Overview 13
PICSO HF 13
PICSO HF Product Overview 13
PICSO Impulse System 14
PICSO Impulse System Product Overview 14
PICSO Impulse System Clinical Trial 15
PiCSOAMI Impulse Console – CABG 16
PiCSOAMI Impulse Console – CABG Product Overview 16
PiCSOAMI Impulse Console – CABG Clinical Trial 17
Miracor Medical Systems GmbH – Key Competitors 18
Miracor Medical Systems GmbH – Key Employees 19
Miracor Medical Systems GmbH – Locations And Subsidiaries 20
Head Office 20
Other Locations & Subsidiaries 20
Recent Developments 21
Miracor Medical Systems GmbH, Recent Developments 21
Jun 06, 2017: Miracor Announces Positive Interim Clinical Data with Novel PiCSO Impulse System for AMI Patients 21
Dec 10, 2015: Antonio Colombo, MD appointed Member of the Scientific Advisory Council of Miracor Medical Systems 21
Oct 29, 2015: Miracor’s PiCSO Impulse System Highlighted as Novel Therapy for Cardioprotected PCI at TCT 2015 in San Francisco 22
Sep 21, 2015: Miracor Medical Systems Launches PiCSO Impulse System In Asia 22
Jun 30, 2015: Miracor Medical Systems appoints international Scientific Advisory Council 23
Mar 31, 2015: Miracor Medical Systems Increases Clinical and Commercial Activities in the UK 24
Jan 08, 2015: Miracor Medical Systems receives additional funding to accelerate clinical validation and commercialization of its PICSO Impulse System 24
Sep 25, 2014: Clinical trial results presented at ‘TCT 2014’ show enhanced myocardial recovery in Acute Myocardial Infarction patients treated with the Miracor PICSO Impulse System 25
Sep 09, 2014: New clinical trial results for Miracor’s PICSO Impulse System in Acute Myocardial Infarction will be reported at ‘TCT 2014’ 26
Jul 22, 2014: Miracor Medical Systems begins European launch of its next-generation PICSO Impulse System, designed to reduce severe heart attack impairment when used as an adjunct therapy with angioplasty in acute STEMI and NSTEMI patients 27
Appendix 28
Methodology 28
About GlobalData 30
Contact Us 30
Disclaimer 31

List of Tables
Miracor Medical Systems GmbH Pipeline Products and Ongoing Clinical Trials Overview 4
Miracor Medical Systems GmbH Pipeline Products by Equipment Type 5
Miracor Medical Systems GmbH Pipeline Products by Indication 6
Miracor Medical Systems GmbH Ongoing Clinical Trials by Trial Status 6
Miracor Medical Systems GmbH, Key Facts 7
Miracor Medical Systems GmbH, Major Products and Services 8
Miracor Medical Systems GmbH Number of Pipeline Products by Development Stage 9
Miracor Medical Systems GmbH Pipeline Products Summary by Development Stage 10
Miracor Medical Systems GmbH Ongoing Clinical Trials by Trial Status 11
Miracor Medical Systems GmbH Ongoing Clinical Trials Summary 12
PICSO HF - Product Status 13
PICSO HF - Product Description 13
PICSO Impulse System - Product Status 14
PICSO Impulse System - Product Description 14
PICSO Impulse System - Oxford Acute Myocardial Infarction-pressure-controlled Intermittent Coronary Sinus Occlusion in STEMI: OxAMI-PICSO study 15
PICSO Impulse System - Pressure Controlled Intermittent Coronary Sinus Occlusion as an Adjunct to PCI in Acute Coronary Syndrome. (An Observational Study Evaluating the Effect of PICSO Treatment Concomitant to pPCI in Patients with Anterior NSTEMI or Following pPCI in STEMI) (An Observational Study Evaluating the Effect of PICSO Treatment Concomitant to PPCI in Patients with Anterior NSTEMI or Following pPCI in STEMI) 15
PiCSOAMI Impulse Console – CABG - Product Status 16
PiCSOAMI Impulse Console – CABG - Product Description 16
PiCSOAMI Impulse Console – CABG - Pressure Controlled Intermittent Coronary Sinus Occlusion as an Adjunct to PCI in Acute Coronary Syndrome. (An Observational Study Evaluating the Effect of PICSO Treatment Concomitant to pPCI in Patients with Anterior NSTEMI or Following pPCI in STEMI) (An Observational Study Evaluating the Effect of PICSO Treatment Concomitant to PPCI in Patients with Anterior NSTEMI or Following pPCI in STEMI) 17
Miracor Medical Systems GmbH, Key Employees 19
Miracor Medical Systems GmbH, Subsidiaries 20
Glossary 29

★海外企業調査レポート[Miracor Medical Systems GmbH:製品パイプライン分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Hyundai Heavy Industries Co., Ltd.:戦略・SWOT・企業財務分析
    Hyundai Heavy Industries Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Hyundai Heavy Industries Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • CCA Industries, Inc.:企業の戦略・SWOT・財務情報
    CCA Industries, Inc. - Strategy, SWOT and Corporate Finance Report Summary CCA Industries, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • GridPoint, Inc.-エネルギー分野:企業M&A・提携分析
    Summary GridPoint, Inc. (Gridpoint), a subsidiary of Twenty First Century Utilities LLC, is a provider of data-driven energy management systems. The company offers a wide range of energy management hardware including control, equipment-level sub-metering and advanced monitoring devices such as contr …
  • Exonate Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Exonate Ltd (Exonate) is a biopharmaceutical company that discovers and develops small molecule drugs, which modulates the alternative mRNA splicing for the treatment of unmet medical needs. The company’s alternative mRNA splicing is modulated in disease states that results in the pathologic …
  • Seaboard Corp (SEB):企業の財務・戦略的SWOT分析
    Seaboard Corp (SEB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Hanmi Pharmaceuticals Co Ltd (128940):企業の財務・戦略的SWOT分析
    Hanmi Pharmaceuticals Co Ltd (128940) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • Grupa Lotos SA (LTS):企業の財務・戦略的SWOT分析
    Grupa Lotos SA (LTS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Fujirebio Europe NV:企業の戦略的SWOT分析
    Fujirebio Europe NV - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Diebold Nixdorf, Incorporated:企業の戦略・SWOT・財務分析
    Diebold Nixdorf, Incorporated - Strategy, SWOT and Corporate Finance Report Summary Diebold Nixdorf, Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • EWE AG:企業の戦略的SWOT分析
    EWE AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • XState Resources Ltd (XST):企業の財務・戦略的SWOT分析
    Summary XState Resources Ltd (XST) is an oil and gas exploration and development company. The company’s business activities include acquisition, exploration, production and development of oil and gas assets. It holds interest in producing gas wells and associated land leases and production and pipel …
  • Cabela’S Inc:企業の戦略・SWOT・財務分析
    Cabela'S Inc - Strategy, SWOT and Corporate Finance Report Summary Cabela'S Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Amazon.com, Inc.:戦略・SWOT・企業財務分析
    Amazon.com, Inc. - Strategy, SWOT and Corporate Finance Report Summary Amazon.com, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Roquette Freres SA:企業の戦略的SWOT分析
    Roquette Freres SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Layne Christensen Co (LAYN):石油・ガス:M&Aディール及び事業提携情報
    Summary Layne Christensen Company (Layne) is a water management, construction and drilling company. It provides solutions to essential natural resources such as water, mineral and energy. The company’s service portfolio includes hydrological studies, site selection, well design, drilling, well rehab …
  • SandRidge Energy Inc (SD):石油・ガス:M&Aディール及び事業提携情報
    Summary SandRidge Energy Inc (SandRidge) is an upstream energy company. It develops, explores for, and produces oil and natural gas in the Mid-Continent and Rockies regions of the US. In Mid-Continent, the company operates assets in Oklahoma and Kansas. In Rockies, SandRidge operates assets within t …
  • Metro AG:戦略・SWOT・企業財務分析
    Metro AG - Strategy, SWOT and Corporate Finance Report Summary Metro AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Mizuho Trust & Banking Co Ltd:企業の戦略・SWOT・財務情報
    Mizuho Trust & Banking Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Mizuho Trust & Banking Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Toma Biosciences Inc-製薬・医療分野:企業M&A・提携分析
    Summary Toma Biosciences Inc (Toma Biosciences) is a biotechnology company that provides genome sequencing solutions. The company launched TOMA OS-Seq cancer assay to laboratories and researchers for the changes in tumors. Its products include reagent kits developed to detect genomic changes in canc …
  • Generex Biotechnology Corp (GNBT):企業の財務・戦略的SWOT分析
    Generex Biotechnology Corp (GNBT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆